Good morning :)
Place Order
Add to Watchlist

Sun Pharmaceutical Industries Ltd

SUNPHARMA

Sun Pharmaceutical Industries Ltd

SUNPHARMA
Health CarePharmaceuticals
LargecapWith a market cap of ₹3,99,681 cr, stock is ranked 16
Low RiskStock is 1.47x as volatile as Nifty
1,714.252.91% (+48.45)
1,714.252.91% (+48.45)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹3,99,681 cr, stock is ranked 16
Low RiskStock is 1.47x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹3,99,681 cr, stock is ranked 16
Low RiskStock is 1.47x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
41.745.960.81%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
46.016.090.55%

Forecast & Ratings

Detailed Forecast 
68%
Analysts have suggested that investors can buy this stock

from 34 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.

Investor Presentation

View older 

Sep 11, 2023

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 10.64%, vs industry avg of 8.96%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 13.29% to 13.56%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 29.15%, vs industry avg of 15.15%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue29,145.2832,201.5927,328.2230,091.4033,489.0934,357.3139,729.9644,520.2049,887.1749,851.04
Raw Materialssubtract6,724.158,402.377,193.988,302.088,929.609,328.3010,459.1511,349.0710,370.4835,968.04
Power & Fuel Costsubtract545.44525.09559.97613.60621.89627.09702.78830.05760.78
Employee Costsubtract4,772.314,902.305,367.055,967.096,362.356,862.237,300.838,296.039,429.06
Selling & Administrative Expensessubtract5,219.205,224.614,727.005,350.336,995.376,283.417,366.889,482.3611,033.19
Operating & Other expensessubtract3,752.782,434.803,983.833,739.603,214.786,235.537,147.912,452.834,410.66
Depreciation/Amortizationsubtract1,037.531,264.751,499.841,753.252,052.782,079.952,143.742,529.432,556.642,556.64
Interest & Other Itemssubtract523.24399.80517.57555.25302.73141.43127.35172.00238.47238.47
Taxes & Other Itemssubtract2,024.922,083.501,383.281,144.781,244.66-104.451,208.59934.851,511.511,511.51
EPS20.3028.988.7311.1115.6912.1013.6435.3239.9139.91
DPS1.003.502.002.754.007.5010.0011.5013.5012.50
Payout ratio0.050.120.230.250.250.620.730.330.340.31

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2014

Annual Report Unavailable

Investor Presentation

Apr 7PDF
FY 2015

Annual Report Unavailable

Investor Presentation

Mar 25PDF
FY 2016

Annual Report Unavailable

FY 2017

Annual Report Unavailable

FY 2018

Annual Report Unavailable

FY 2019

Annual Report Unavailable

FY 2022

Annual report

PDF

Investor Presentation

Mar 24PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 28PDF
Jan 16PDF
Sep 16PDF
FY 2024

Annual report

PDF

Investor Presentation

Sep 11PDF
Jul 21PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Sun Pharmaceutical Industries Ltd41.745.960.81%
Zydus Lifesciences Ltd31.445.490.25%
Cipla Ltd29.395.110.87%
Dr Reddy's Laboratories Ltd20.464.040.58%

Price Comparison

Compare SUNPHARMA with any stock or ETF
Compare SUNPHARMA with any stock or ETF
SUNPHARMA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.48%12.78%6.50%17.23%9.01%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun12.91%13.16%13.07%12.93%12.21%12.78%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Sun Pharmaceutical Industries Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential Value Discovery Fund - Growth - Direct Plan

Growth
0.5867%5.50%-0.60%9/95 (-2)
ICICI Prudential Bluechip Fund - Growth - Direct Plan

Growth
0.3577%2.58%-0.11%11/80 (0)
ICICI Prudential India Opportunities Fund - Growth - Direct Plan

Growth
0.3548%6.74%3.05%3/84 (+4)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Sun Pharmaceutical Industries Ltd

Events

Dividend Trend

Increasing Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

SUNPHARMA has increased dividends consistently over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.81%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.10 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 12, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Jul 12, 2024

Cash Dividend

Ex DateEx DateFeb 9, 2024

Interim
Interim | Div/Share: ₹8.50

Dividend/Share

8.50

Ex DateEx Date

Feb 9, 2024

Cash Dividend

Ex DateEx DateJul 28, 2023

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Jul 28, 2023

Cash Dividend

Ex DateEx DateFeb 8, 2023

Interim
Interim | Div/Share: ₹7.50

Dividend/Share

7.50

Ex DateEx Date

Feb 8, 2023

Cash Dividend

Ex DateEx DateAug 19, 2022

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Aug 19, 2022

News & Opinions

Sun Pharma receives US FDA approval for drug to treat alopecia areata

8 hours agoBusiness Standard

Bulls back on D-Street: Investors gain Rs 7 lakh crore as Sensex, Nifty rebound

14 hours agoBusiness Today

Sun Pharma receives USFDA approval for LEQSELVI (deuruxolitinib) 8 mg tablets

16 hours agoBusiness Standard
Corporate
Sun Pharma receives USFDA approval for LEQSELVI' (deuruxolitinib) 8 mg tablets

Sun Pharmaceuticals Industries announced that the U.S. Food and Drug Administration (FDA) approved LEQSELVI' (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. 'LEQSELVI offers a new and effective solution that will significantly enhance options for long-suffering patients battling severe alopecia areata and their physicians,' said Abhay Gandhi, CEO, North America Business, Sun Pharma. 'Our fast-growing dermatology business is excited to add this novel treatment to its portfolio.Powered by Capital Market - Live

17 hours agoCapital Market - Live
Spotlight
Sun Pharmaceuticals Industries Ltd spurts 1.88%, rises for fifth straight session

Sun Pharmaceuticals Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 1697.15, up 1.88% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 1.28% on the day, quoting at 24718.65. The Sensex is at 80971.98, up 1.16%. Sun Pharmaceuticals Industries Ltd has gained around 11.93% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has gained around 10% in last one month and is currently quoting at 21105.5, up 1.71% on the day. The volume in the stock stood at 25.62 lakh shares today, compared to the daily average of 19.27 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1705.5, up 1.91% on the day. Sun Pharmaceuticals Industries Ltd is up 49.54% in last one year as compared to a 25.73% jump in NIFTY and a 43.88% jump in the Nifty Pharma index.The PE of the stock is 130.91 based on TTM earnings ending March 24.Powered by Capital Market - Live

18 hours agoCapital Market - Live

Sun Pharma hits all time high on US FDA nod for alopecia drug ‘Leqselvi’

19 hours agoBusiness Standard

Sun Pharma gets US FDA nod for its specialty drug against baldness

19 hours agoEconomic Times
Live Market Update
Nifty above 24,600 level; IT shares in demand

The domestic equity indices traded with robust gains in the mid-morning trade. The Nifty scaled above the 24,600 level. IT shares gained after declining in the past trading session. At 11:30 IST, the barometer index, the S&P BSE Sensex, was up 646.71 points or 0.80% to 80,678.94. The Nifty 50 index rallied 235.35 points or 0.95% to 24,638.95. The broader market outperformed the headline indices. The S&P BSE Mid-Cap index gained 1.70% and the S&P BSE Small-Cap index added 1.11%. The market breadth was strong. On the BSE, 2,701 shares rose and 1,040 shares fell. A total of 115 shares were unchanged. Buzzing Index: The Nifty IT index added 1.96% to 40,839.70. The index shed 0.03% in the past trading sessions. Mphasis (up 6.77%), LTIMindtree (up 2.61%), Infosys (up 2.53%), Wipro (up 2.25%), HCL Technologies (up 2.11%), Persistent Systems (up 2.01%), Tata Consultancy Services (up 1.37%), Coforge (up 0.78%), L&T Technology Services (up 0.1%) advanced. Stocks in Spotlight: Sun Pharmaceutical Industries gained 2.58% after the pharma major said that it has received approval from the U.S. Food and Drug Administration (US FDA) for LEQSELVI (deuruxolitinib), an oral JAK Inhibitor for the treatment of severe alopecia areata. VST Industries added 2.79% after the company said that its board has recommended issue of bonus shares in the ratio of 10:1, i.e. ten new bonus equity shares of Rs 10 each for every one existing fully paid equity share of Rs 10 each. Tech Mahindra shed 0.29%. The IT major's consolidated net profit jumped 28.82% to Rs 851.5 crore on 1.04% rise in revenue from operations to Rs 13,005.5 crore in Q1 FY25 over in Q1 FY24. Global Markets: Asian stocks traded mixed on Friday as investors digested Tokyo's latest inflation data and awaited key U.S. economic figures. Japan's headline inflation eased slightly to 2.2% in July, while core inflation held steady at 2.2%. The market's focus now shifts to the U.S., where the release of the personal consumption expenditure (PCE) index ' the Federal Reserve's preferred inflation gauge ' is expected to influence interest rate expectations. Meanwhile, U.S. stocks experienced a rotation away from technology shares on Thursday, with the Nasdaq Composite and S&P 500 declining. The Dow Jones Industrial Average bucked the trend with a modest gain. This shift is a common occurrence during bull markets as market leadership evolves.Powered by Capital Market - Live

20 hours agoCapital Market - Live

Sun Pharma’s drug to treat alopecia areata gets USFDA nod

20 hours agoEconomic Times

Sun Pharmaceutical Industries Share Price Today Live Updates: Sun Pharma Closes at Rs 1665.80 with 6.19% Weekly Gain - The Economic Times

21 hours agoEconomic Times